<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Captopril: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Captopril: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Captopril: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9196" href="/d/html/9196.html" rel="external">see "Captopril: Drug information"</a> and <a class="drug drug_patient" data-topicid="11677" href="/d/html/11677.html" rel="external">see "Captopril: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708658"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">When pregnancy is detected, discontinue captopril as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866187"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Capto;</li>
<li>CO Captopril;</li>
<li>TEVA-Captopril</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1051458"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Angiotensin-Converting Enzyme (ACE) Inhibitor</span>;</li>
<li>
<span class="list-set-name">Antihypertensive Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462393"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Use is frequently associated with acute kidney injury (including renal failure) in premature and term neonates with cardiac disease prescribed standard doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18605972','lexi-content-ref-22477817','lexi-content-ref-24233240']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18605972','lexi-content-ref-22477817','lexi-content-ref-24233240'])">Ref</a></span>); some experts suggest avoiding use until corrected PMA ≥44 weeks when possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33223015','lexi-content-ref-29808264']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33223015','lexi-content-ref-29808264'])">Ref</a></span>); use with caution and monitor closely. To minimize risk of hypotension, consider lower doses in patients who are sodium and water depleted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Domonoske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Domonoske.1'])">Ref</a></span>). Carefully review to ensure appropriate dosing is given; use lowest effective dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3fae7b56-e1d5-416b-80e5-9f0550fd48e0">Heart failure; hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure (afterload reduction); hypertension: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Premature and term neonates: Oral: Initial: 0.01 mg/kg/dose every 8 to 12 hours; usual initial range: 0.01 to 0.05 mg/kg/dose; some experts suggest higher initial doses up to 0.1 mg/kg/dose every 8 to 24 hours in term neonates; monitor closely for hypotension, especially when using higher initial doses; titrate dose as needed up to a maximum of 0.5 mg/kg/dose every 6 to 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3031972','lexi-content-ref-Domonoske.1','lexi-content-ref-33223015','lexi-content-ref-3923176','lexi-content-ref-18605972','lexi-content-ref-3294363','lexi-content-ref-29808264']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3031972','lexi-content-ref-Domonoske.1','lexi-content-ref-33223015','lexi-content-ref-3923176','lexi-content-ref-18605972','lexi-content-ref-3294363','lexi-content-ref-29808264'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F145389"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86fd017b-f098-427e-b843-c16a24638f11">Heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure (afterload reduction):</b> Limited data available: <b>Note:</b> Initiate therapy at lower end of range and titrate upward to prevent symptomatic hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16494512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16494512'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: Oral: Initial: 0.1 to 0.3 mg/kg/dose every 6 to 24 hours; titrate as needed; reported daily dose range: 0.3 to 3.5 mg/kg/<b>day</b> divided every 6 to 12 hours; maximum daily dose: 6 mg/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3031972','lexi-content-ref-Park.2014','lexi-content-ref-3308715','lexi-content-ref-3284479']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3031972','lexi-content-ref-Park.2014','lexi-content-ref-3308715','lexi-content-ref-3284479'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: Initial: 0.3 to 0.5 mg/kg/dose every 8 to 12 hours; titrate as needed; in clinical trials, usual reported dosage range was 0.9 to 3.9 mg/kg/<b>day</b> in divided doses; maximum daily dose: 6 mg/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3031972','lexi-content-ref-16494512','lexi-content-ref-Park.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3031972','lexi-content-ref-16494512','lexi-content-ref-Park.2014'])">Ref</a></span>); in adults, the target dose is 150 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23747642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23747642'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b> Limited data available: <b>Note:</b> Dosage must be titrated according to patient's response; use lowest effective dose; lower doses (~<sup>1</sup>/<sub>2</sub> of those listed) should be used in patients who are sodium- and water-depleted due to diuretic therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-directed dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: Oral: Initial: 0.05 mg/kg/dose every 6 to 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377'])">Ref</a></span>); higher initial doses of 0.15 to 0.3 mg/kg/dose every 6 to 24 hours have been recommended by some experts and may be needed in patients with severe hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3889818','lexi-content-ref-Park.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3889818','lexi-content-ref-Park.2014'])">Ref</a></span>); titrate dose carefully upward as needed to maximum of 6 mg/kg/<b>day</b>; monitor for hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377','lexi-content-ref-Park.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377','lexi-content-ref-Park.2014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Oral: Initial: 0.3 to 0.5 mg/kg/dose every 8 hours; may titrate as needed up to maximum daily dose: 6 mg/kg/<b>day</b> in 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377','lexi-content-ref-NIH.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377','lexi-content-ref-NIH.2012'])">Ref</a></span>); in adults, the dose is titrated as needed up to 150 mg/<b>day </b>(usual dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Fixed dosing: Adolescents: Oral: Initial: 12.5 to 25 mg/dose every 8 to 12 hours; increase by 25 mg/dose at 1- to 2-week intervals based on patient response; in adults, the dose is increased as needed up to 150 mg/<b>day </b>(usual dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Park.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Park.2014'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51083891"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: The following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>). <b>Note:</b> Renally adjusted dose recommendations are based on doses of 0.1 to 0.5 mg/kg/dose every 6 to 8 hours; maximum daily dose: 6 mg/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:2em;">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 75% of dose</p>
<p style="text-indent:-2em;margin-left:2em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose</p>
<p style="text-indent:-2em;margin-left:2em;">Intermittent hemodialysis: Administer 50% of dose</p>
<p style="text-indent:-2em;margin-left:2em;">Peritoneal dialysis (PD): Administer 50% of dose</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous renal replacement therapy (CRRT): Administer 75% of dose</p></div>
<div class="block dohp drugH1Div" id="F51090246"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F145368"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9196" href="/d/html/9196.html" rel="external">see "Captopril: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c422ce2-49d1-404f-9c62-15c216a263dd">Acute coronary syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute coronary syndrome:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Non-ST elevation acute coronary syndrome:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Patients should be hemodynamically stable before initiation. Use as a component of an appropriate medical regimen, which may also include antiplatelet agent(s), a beta-blocker, and a statin. Continue angiotensin-converting enzyme inhibitor therapy indefinitely for patients with concurrent diabetes, left ventricular ejection fraction ≤40%, hypertension, or stable chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25249586']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25249586'])">Ref</a></span>). Dosing is based on general dosing range in manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 6.25 mg; if tolerated, increase to 12.5 mg 3 times daily; then increase to 25 mg 3 times daily during next several days and then gradually increase over next several weeks to target dose of 50 mg 3 times daily as tolerated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>ST-elevation myocardial infarction:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Patients should be hemodynamically stable before initiation. Use as a component of an appropriate medical regimen, which may also include antiplatelet agent(s), a beta-blocker, and a statin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304'])">Ref</a></span>). Dosing is based on general dosing range in manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 6.25 mg; if tolerated, increase to 12.5 mg 3 times daily; then increase to 25 mg 3 times daily during next several days and then gradually increase over next several weeks to target dose of 50 mg 3 times daily as tolerated.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b43376ec-cceb-40f9-ad1e-9137f312af09">Heart failure with reduced ejection fraction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>If tolerated<b>, </b>an angiotensin II receptor-neprilysin inhibitor is generally preferred over an angiotensin-converting enzyme inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 6.25 mg 3 times daily; increase dose (eg, double) as tolerated every ≥1 to 2 weeks to a target dose of 50 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>). In hospitalized patients, may titrate more rapidly as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyer.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients who warrant combination therapy (BP &gt;20/10 mm Hg above goal or suboptimal response to initial monotherapy), may use with another appropriate agent (eg, long-acting dihydropyridine calcium channel blocker or thiazide diuretic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>). For severe asymptomatic hypertension, may consider short-term use for BP lowering (eg, over hours) if there is concern that severe BP elevation will precipitate an acute cardiovascular event, such as in patients with known aortic or intracranial aneurysms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Varon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Varon.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 6.25 to 25 mg 2 to 3 times daily; for patients in an acute care setting, may titrate as frequently as every 8 hours (based on pharmacokinetic properties), as needed, up to 50 mg 3 times daily; if additional BP control is needed, consider combination therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Manu.1'])">Ref</a></span>). In an ambulatory setting, patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication adjustment within 1 week. Consider transitioning to an appropriate longer-acting antihypertensive to improve adherence for chronic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mann.1','lexi-content-ref-Varon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mann.1','lexi-content-ref-Varon.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2077fe7f-3b26-4f56-b690-0a9b9ad8a8ea">Primary aldosteronism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary aldosteronism (diagnostic agent) (off-label use): Note:</b> Administer after patient has been sitting or standing for at least 1 hour.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 25 to 50 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11408392','lexi-content-ref-26934393','lexi-content-ref-20117105']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11408392','lexi-content-ref-26934393','lexi-content-ref-20117105'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d8b6822-d348-4d03-bd66-4ea05b5dd0a9">Proteinuric chronic kidney disease, diabetic or nondiabetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Proteinuric </b>
<b>chronic kidney disease, diabetic (labeled use) or nondiabetic (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 12.5 to 25 mg two to three times daily depending on initial BP; titrate gradually (eg, by doubling the dose every 2 to 4 weeks) up to the maximally tolerated dose, not to exceed 50 mg three times daily. If proteinuria target is not met despite optimized dosage, consider additional therapies (eg, sodium-glucose cotransporter-2 inhibitor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cattran.1','lexi-content-ref-34556256','lexi-content-ref-36272764','lexi-content-ref-3073076','lexi-content-ref-Perkovic.1','lexi-content-ref-3906398','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cattran.1','lexi-content-ref-34556256','lexi-content-ref-36272764','lexi-content-ref-3073076','lexi-content-ref-Perkovic.1','lexi-content-ref-3906398','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991175"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Kidney impairment prior to treatment initiation:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6381858']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6381858'])">Ref</a></span>): <b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to &lt;50 mL/minute: Initial: Administer the usual indication-specific dose every 12 to 24 hours. Titrate slowly based on tolerability and response; consider a maximum dose of 50 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: Initial: Administer the usual indication-specific dose every 24 hours. Titrate slowly based on tolerability and response; consider a maximum dose of 50 mg every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (~35%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6381858']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6381858'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Avoid use if an AN69 hemofilter is used (associated with anaphylactoid reaction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10879671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10879671'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: Administer the usual indication-specific dose every 24 hours. When scheduled dose falls on a dialysis day, administer after dialysis. Titrate slowly based on tolerability and response; consider a maximum dose of 50 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6381858','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6381858','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Dialyzable: <b>Oral:</b> Initial: Administer the usual indication-specific dose every 24 hours. Titrate slowly based on tolerability and response; consider a maximum dose of 50 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3025754','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3025754','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT: Note:</b> Avoid use if an AN69 hemofilter is used (associated with anaphylactoid reaction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10879671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10879671'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: Administer usual indication-specific dose every 12 to 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Titrate slowly based on tolerability and response; consider a maximum dose of 50 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): Note: </b>Avoid use if an AN69 hemofilter is used (associated with anaphylactoid reaction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10879671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10879671'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: Administer usual indication-specific dose every 12 to 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). When scheduled dose falls on a PIRRT day, administer after PIRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Titrate slowly based on tolerability and response; consider a maximum dose of 50 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Alterations in kidney function during treatment:</b></i>Small, transient increases in serum creatinine are likely to occur within 4 weeks following initiation of therapy or an increase in dose. If serum creatinine increases by &gt;30%, review for possible etiologies (eg, acute kidney injury, volume depletion, concomitant medications, renal artery stenosis) before determining if dose reduction or discontinuation of captopril therapy should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32998798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32998798'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988201"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); use with caution, particularly in patients with ascites due to cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-23463403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-23463403'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F56280423"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use may be associated with <b>increased blood urea nitrogen</b> (azotemia) and <b>increased serum creatinine</b>, resulting in <b>oliguria </b>and <b>acute kidney injury</b> (AKI). Increases in serum creatinine are expected due to pharmacologic mechanism and generally stabilize within 20% to 30% of the baseline; higher increases may indicate high efferent tone (such as with hypovolemia, congestive heart failure, or renal artery stenosis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.2012','lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.2012','lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Related to pharmacologic action; inhibits efferent arteriolar vasoconstriction, which can lead to a reduction in the glomerular filtration rate (GFR). Kidney hypoperfusion from systemic hypotension may also occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; increases in serum creatinine generally occur within 2 weeks of initiation and stabilize within 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10724055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10724055'])">Ref</a></span>). However, more immediate increases can occur in patients with other risk factors for AKI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22754420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22754420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with low renal blood flow whose GFR is dependent on efferent arteriolar vasoconstriction by angiotensin II (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25018935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25018935'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">- Low effective circulating volume (sodium or volume depletion)</p>
<p style="text-indent:-2em;margin-left:8em;">- Congestive heart failure</p>
<p style="text-indent:-2em;margin-left:8em;">- Hypotension or shock</p>
<p style="text-indent:-2em;margin-left:8em;">- Renal artery stenosis</p>
<p style="text-indent:-2em;margin-left:6em;">• High dose at initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent diuretic and/or nonsteroidal anti-inflammatory drug use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27490717','lexi-content-ref-31888533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27490717','lexi-content-ref-31888533'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Angioedema</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angioedema </b>may occur rarely; edema may manifest in the head and neck (potentially compromising airway) or the intestine (presenting as abdominal pain). Use is contraindicated in patients with idiopathic or hereditary angioedema or previous angioedema associated with any angiotensin-converting enzyme inhibitors or neprilysin inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28377081','lexi-content-ref-28994183','lexi-content-ref-29884969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28377081','lexi-content-ref-28994183','lexi-content-ref-29884969'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to pharmacologic action (ie, increased bradykinin and substance P, vascular permeability, vasodilation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25058867','lexi-content-ref-29884969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25058867','lexi-content-ref-29884969'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may occur at any time during treatment. Most cases occur within the first week of therapy but may also occur years after therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28377081','lexi-content-ref-2840522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28377081','lexi-content-ref-2840522'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Black patients (estimated 4- to 5-fold higher risk); the mechanism for this is not completely understood but may be related to genetic variants) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28377081','lexi-content-ref-28994183','lexi-content-ref-8689816','lexi-content-ref-16043683','lexi-content-ref-29884969','lexi-content-ref-32496628','lexi-content-ref-18413488','lexi-content-ref-31835086','lexi-content-ref-20625347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28377081','lexi-content-ref-28994183','lexi-content-ref-8689816','lexi-content-ref-16043683','lexi-content-ref-29884969','lexi-content-ref-32496628','lexi-content-ref-18413488','lexi-content-ref-31835086','lexi-content-ref-20625347'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29884969','lexi-content-ref-18413488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29884969','lexi-content-ref-18413488'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Smoking history (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29884969','lexi-content-ref-15482412']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29884969','lexi-content-ref-15482412'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous history of angioedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28377081','lexi-content-ref-9218671']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28377081','lexi-content-ref-9218671'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25058867','lexi-content-ref-16043683','lexi-content-ref-29884969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25058867','lexi-content-ref-16043683','lexi-content-ref-29884969'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Seasonal allergies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16043683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16043683'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of mechanistic target of rapamycin (mTOR) inhibitors (eg, everolimus) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28994183','lexi-content-ref-20093343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28994183','lexi-content-ref-20093343'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of neprilysin inhibitor (contraindicated)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cough</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A dry, hacking, nonproductive <b>cough</b> that is typically associated with tickling or scratching in the throat may occur with angiotensin-converting enzyme inhibitors (ACEI) in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20130570','lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-10644922','lexi-content-ref-8703645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20130570','lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-10644922','lexi-content-ref-8703645'])">Ref</a></span>). Recurrence is likely with rechallenge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8862965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8862965'])">Ref</a></span>). Resolution of cough typically occurs 1 to 4 weeks after ACEI discontinuation but may persist for up to 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-8703645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-8703645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Various proposed mechanisms. May be related to pharmacologic action (increase in bradykinin and substance P, resulting in accumulation in the lungs and bronchoconstriction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16428706','lexi-content-ref-1616218']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16428706','lexi-content-ref-1616218'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; within hours to 4 weeks after initiation but can be delayed for up to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-8703645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16428706','lexi-content-ref-1616218','lexi-content-ref-8703645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28767167','lexi-content-ref-7848615','lexi-content-ref-25992489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28767167','lexi-content-ref-7848615','lexi-content-ref-25992489'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Possibly certain genetic variants (some of which may be independent of the bradykinin pathway) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28084903','lexi-content-ref-30672376','lexi-content-ref-32397904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28084903','lexi-content-ref-30672376','lexi-content-ref-32397904'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dermatologic reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Various cutaneous reactions have been reported, including <b>skin rash</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3064605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3064605'])">Ref</a></span>) and rarer events, such as <b>toxic epidermal necrolysis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12639167','lexi-content-ref-10498172']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12639167','lexi-content-ref-10498172'])">Ref</a></span>), <b>lichenoid eruption</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18489011','lexi-content-ref-7955473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18489011','lexi-content-ref-7955473'])">Ref</a></span>), <b>drug rash with eosinophilia and systemic symptoms </b>(DRESS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31045940','lexi-content-ref-24030372']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31045940','lexi-content-ref-24030372'])">Ref</a></span>), linear IgA bullous dermatosis (LABD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9732010','lexi-content-ref-7904616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9732010','lexi-content-ref-7904616'])">Ref</a></span>), and <b>pemphigus</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33418246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33418246'])">Ref</a></span>). Skin rash is often transitory, lasting for hours or days and may resolve upon continued therapy with captopril (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3064605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3064605'])">Ref</a></span>). <b>Skin photosensitivity</b> has also been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33491908']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33491908'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Skin rash: Not well described; may be dose-related (ie, enhances cutaneous histamine reaction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3064605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3064605'])">Ref</a></span>) or non–dose-related.</p>
<p style="text-indent:-2em;margin-left:6em;">Pemphigus: Unknown, but the sulfhydryl group found in captopril may cause biochemical modifications of antigens or bind to desmosomal proteins, resulting in autoantibody formation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33418246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33418246'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions including TEN and DRESS: Non–dose-related; immunologic (ie, involving a T-cell mediated drug-specific immune response) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Skin rash: Can occur in the first few weeks of treatment, although most cases occur within the first few days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3064605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3064605'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Lichenoid eruptions: May occur up to 2 years after captopril initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7955473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7955473'])">Ref</a></span>). The mean time interval between initiation of captopril and pemphigus onset was ~6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33418246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33418246'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions including DRESS and TEN: Varied; typically 1 to 8 weeks after drug exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31045940','lexi-content-ref-26120552','lexi-content-ref-24030372','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31045940','lexi-content-ref-26120552','lexi-content-ref-24030372','lexi-content-ref-NICE.2014'])">Ref</a></span>), although may occur within days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12639167']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12639167'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Skin rash:</p>
<p style="text-indent:-2em;margin-left:8em;">- High doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3064605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3064605'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2937293','lexi-content-ref-3064605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2937293','lexi-content-ref-3064605'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactions with other angiotensin-converting enzyme inhibitors not consistent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31045940','lexi-content-ref-9874028','lexi-content-ref-3064605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31045940','lexi-content-ref-9874028','lexi-content-ref-3064605'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hematologic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Rare but serious bone marrow suppression with decreases in hematological cell lines have occurred in patients taking captopril, which can manifest as <b>neutropenia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6354930','lexi-content-ref-1614676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6354930','lexi-content-ref-1614676'])">Ref</a></span>), <b>agranulocytosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3526889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3526889'])">Ref</a></span>)<i>, </i>
<b>thrombocytopenia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6337741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6337741'])">Ref</a></span>), <b>hemolytic anemia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17323037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17323037'])">Ref</a></span>), or <b>pancytopenia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10606162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10606162'])">Ref</a></span>). Most cases have been reported in adults; a few pediatric cases have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8255797','lexi-content-ref-15228574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8255797','lexi-content-ref-15228574'])">Ref</a></span>). Some reported cases have been fatal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6788292','lexi-content-ref-3526889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6788292','lexi-content-ref-3526889'])">Ref</a></span>), whereas in other cases, bone marrow recovery occurred after captopril reintroduction without incident (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6110936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6110936'])">Ref</a></span>). Reports of bone marrow suppression appear to be more common in patients taking captopril than in patients taking other angiotensin-converting enzyme inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27335175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27335175'])">Ref</a></span>). Due to the infrequency of reports on bone marrow suppression and the low-quality of the available evidence, a causal relationship between captopril and hematologic effects has not been demonstrated. Neutrophil count generally returns to baseline within 2 weeks of discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown, likely idiosyncratic. Postulated mechanisms for bone marrow suppression include an immune-mediated reaction against bone marrow precursor cells or a direct toxic effect of reactive metabolites on blood cells and precursors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27335175','lexi-content-ref-2937293','lexi-content-ref-17323037','lexi-content-ref-10498172']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27335175','lexi-content-ref-2937293','lexi-content-ref-17323037','lexi-content-ref-10498172'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Neutropenia: Varied; usually within 3 months of initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• High captopril doses ≥150 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6753907','lexi-content-ref-3526889','lexi-content-ref-10498172']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6753907','lexi-content-ref-3526889','lexi-content-ref-10498172'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline kidney dysfunction, including renal transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6340620','lexi-content-ref-6753907','lexi-content-ref-10498172']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6340620','lexi-content-ref-6753907','lexi-content-ref-10498172'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent immunosuppressive drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8255797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8255797'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Connective tissue disorders such as systemic lupus erythematosus and scleroderma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6340620','lexi-content-ref-8255797','lexi-content-ref-10498172']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6340620','lexi-content-ref-8255797','lexi-content-ref-10498172'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with Trisomy 21 may be at increased risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8255797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8255797'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperkalemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia </b>(elevated serum potassium) may occur on therapy with angiotensin-converting enzyme inhibitors (ACEI), including captopril (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15295051','lexi-content-ref-20150448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15295051','lexi-content-ref-20150448'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to pharmacologic action; inhibits formation of circulating angiotensin II, which leads to efferent arteriole vasodilation and subsequent lowering of glomerular filtration rate, which lowers potassium elimination. Additionally, interferes with the generation and release of aldosterone from the adrenal cortex, leading to an impairment of potassium excretion from the kidney (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31119681','lexi-content-ref-15295051','lexi-content-ref-20150448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31119681','lexi-content-ref-15295051','lexi-content-ref-20150448'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Disease states associated with hyperkalemia (congestive heart failure, diabetes mellitus, chronic kidney disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31226134','lexi-content-ref-31119681','lexi-content-ref-20150448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31226134','lexi-content-ref-31119681','lexi-content-ref-20150448'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications which cause hyperkalemia (ACEI, angiotensin II receptor antagonists, spironolactone, nonsteroidal anti-inflammatory drugs, beta blockers, heparin, tacrolimus, cyclosporine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31226134','lexi-content-ref-32291375','lexi-content-ref-15295051','lexi-content-ref-21883995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31226134','lexi-content-ref-32291375','lexi-content-ref-15295051','lexi-content-ref-21883995'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Acute kidney injury (elevated BUN and/or serum creatinine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15295051','lexi-content-ref-9437375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15295051','lexi-content-ref-9437375'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High dietary intake of potassium or concomitant use of potassium supplements (including potassium-containing salt substitutes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32291375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32291375'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline elevated potassium level (≥5 mmol/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15295051','lexi-content-ref-9437375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15295051','lexi-content-ref-9437375'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F145328"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (1%), palpitations (1%), tachycardia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (≤2%), pruritus (2%), skin rash (4% to 7%; including maculopapular rash, urticaria; in patients with rash, a positive ANA and/or eosinophilia has been noted in 7% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (≤2%), ageusia (≤4%), anorexia (≤2%), aphthous stomatitis (≤2%), constipation (≤2%), diarrhea (≤2%), dysgeusia (≤4%; diminished taste perception), gastric irritation (≤2%), nausea (≤2%), peptic ulcer (≤2%), vomiting (≤2%), xerostomia (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (in patients with or without renal impairment with no collagen vascular disease: &lt;1%; in patients with impaired renal function and collagen vascular disease [eg, systemic lupus erythematous, scleroderma]: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (≤2%), fatigue (≤2%), headache (≤2%), insomnia (≤2%), malaise (≤2%), paresthesia (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (≤2%), dyspnea (≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris, cardiac failure, flushing, Raynaud's disease</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pallor</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Nephrotic syndrome, oliguria, urinary frequency</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, polyuria, renal insufficiency</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, aplastic anemia,</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia, cerebrovascular accident, cerebrovascular insufficiency, orthostatic hypotension, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Bullous pemphigoid, bullous skin disease (Friedman 1998), dermatitis (Martinez 2011), dermatologic disorder (linear IgA bullous dermatosis) (Friedman 1998), erythema multiforme, exfoliative dermatitis (Solinger 1982), lichenoid eruption (Ben Salem 2008), pemphigus (Ghaedi 2021), skin photosensitivity (Hofmann 2021), Stevens-Johnson syndrome, toxic epidermal necrolysis (Alkurtass 2003)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia (Markusse 1988), hyperkalemia (Weir 2010), hyponatremia (symptomatic)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis (Kocab 2000), dyspepsia, glossitis, pancreatitis (Gorsane 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence, membranous glomerulonephritis (Bailey 1992)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Suarez 1986), eosinophilia, hemolytic anemia (Trimble 2007), pancytopenia (Chisi 1999), positive ANA titer, thrombocytopenia (Kramer 1983)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic necrosis (rare), hepatitis (Vandenburg 1981), jaundice (Crantock 1991)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Nonimmune anaphylaxis (Peces 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Ammar 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, confusion, depression, drowsiness, myasthenia, nervousness, seizure (in infants) (Perlman 1989), visual hallucination (Doane 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, eosinophilic pneumonitis, rhinitis</p></div>
<div class="block coi drugH1Div" id="F145344"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to captopril, any other angiotensin-converting enzyme (ACE) inhibitor, or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; concomitant use with aliskiren in patients with diabetes mellitus; coadministration with or within 36 hours of switching to or from a neprilysin inhibitor (eg, sacubitril).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Concomitant use with aliskiren in patients with moderate to severe kidney impairment (GFR &lt;60 mL/minute/1.73 m<sup>2</sup>).</p></div>
<div class="block war drugH1Div" id="F145325"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cholestatic jaundice: A rare toxicity includes cholestatic jaundice, which may progress to fulminant hepatic necrosis (some fatal); discontinue if marked elevation of hepatic transaminases or jaundice occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Anaphylactic reaction/nonimmune anaphylaxis can occur with angiotensin-converting enzyme (ACE) inhibitors. Severe nonimmune anaphylaxis may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low-density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of nonimmune anaphylaxis have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses). Effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation. Close monitoring of patient is required especially with initial dosing and dosing increases; BP must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use, especially in patients with heart failure where a reduction in systolic BP is a desirable observation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Proteinuria: Total urinary proteins &gt;1 g per day have been reported (&lt;1%); nephrotic syndrome occurred in about one-fifth of proteinuric patients. In most cases, proteinuria subsided or cleared within 6 months (whether or not captopril was continued).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic stenosis: Use with caution in patients with aortic stenosis; may reduce coronary perfusion resulting in ischemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ascites: Generally, avoid use in patients with ascites due to cirrhosis or refractory ascites; if use cannot be avoided in patients with ascites due to cirrhosis, monitor BP and kidney function carefully to avoid rapid development of kidney failure (AASLD [Runyon 2013]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling BP (eg, myocardial infarction [MI], stroke). Fluid replacement, if needed, may restore BP; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs. In a retrospective cohort study of elderly patients (≥65 years of age) with MI and impaired left ventricular function, administration of an ACE inhibitor was associated with a survival benefit, including patients with serum creatinine concentrations &gt;3 mg/dL (265 micromol/L) (Frances 2000).</p>
<p style="text-indent:-2em;margin-left:4em;">• Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant kidney impairment; may be at increased risk for hematologic toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: Use with caution in patients with hypertrophic cardiomyopathy and left ventricular outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition (AHA/ACC [Ommen 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in preexisting kidney insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation, which may lead to further kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Race/Ethnicity: In Black patients, the BP-lowering effects of ACE inhibitors may be less pronounced. The exact mechanism is not known; differences in the renin-angiotensin-aldosterone system, low renin levels, and salt sensitivity more commonly found in Black patients may contribute (Brewster 2013; Helmer 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: In patients on chronic ACE inhibitor therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia; use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss, or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension. However, discontinuation of therapy prior to surgery is controversial. If continued preoperatively, avoidance of hypotensive agents during surgery is prudent (Hillis 2011). Based on current research and clinical guidelines in patients undergoing noncardiac surgery, continuing ACE inhibitors is reasonable in the perioperative period. If ACE inhibitors are held before surgery, it is reasonable to restart postoperatively as soon as clinically feasible (ACC/AHA [Fleisher 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extemporaneous oral solutions: Extemporaneous preparations of liquid formulations may vary; this may affect the rate and extent of absorption causing intrapatient variability regarding dosing and safety profile for the patient; use with caution and monitor closely if dosage formulations are changed (Bhatt 2011; Mulla 2007).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878364"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Neonates and young infants appear to be more sensitive to adverse effects (Gantenbein 2008). ACE inhibitors have been associated with nephrotoxicity in neonates; risk may be higher in preterm neonates; a retrospective study evaluated ACE inhibitor (captopril or enalapril) nephrotoxicity in 206 neonates (term [n=168] and preterm [n=38]) with cardiovascular disease; nearly 42% of neonates were in the pRIFLE (pediatric risk, injury, failure, loss, and end-stage renal disease) category of risk or higher; 30% of all patients were in the renal failure category; when separated out into term and preterm, &gt;50% of preterm neonates were in the renal failure category while receiving an ACE inhibitor and were significantly more likely to be in the renal failure category compared to term neonates (Lindle 2014). Initiate dosing at lower end of the range in preterm neonates.</p>
<p style="text-indent:0em;margin-top:2em;">An observational study of 66 pediatric patients with heart failure reported hypotension in 15% of patients during therapy initiation at typical starting doses; close monitoring in an inpatient setting and low starting doses has been suggested in these patients (Momma 2006; Orchard 2010).</p>
<p style="text-indent:0em;margin-top:2em;">An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1 to 4 weeks after discontinuation of the ACE inhibitor; in pediatric patients, an isolated dry hacking cough lasting &gt;3 weeks was reported in seven of 42 pediatric patients (17%) receiving ACE inhibitors (von Vigier 2000); a review of pediatric randomized-controlled ACE inhibitor trials reported a lower incidence of 3.2% (Baker-Smith 2010). Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.</p></div>
<div class="block foc drugH1Div" id="F145337"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 12.5 mg, 25 mg, 50 mg, 100 mg</p></div>
<div class="block geq drugH1Div" id="F145321"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F145346"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Captopril Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg (per each): $1.27 - $1.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $1.27 - $1.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $2.36 - $2.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $3.09 - $3.81</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866188"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 6.25 mg [DSC], 12.5 mg, 25 mg, 50 mg, 100 mg</p></div>
<div class="block exp drugH1Div" id="F145342"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>1 mg/mL Oral Solution (ASHP Standard Concentration)</b> (ASHP 2017)</p>
<p style="text-indent:-2em;margin-left:2em;">A 1 mg/mL oral solution may be made by allowing two 50 mg tablets to dissolve in 50 mL of distilled water. Add the contents of one 500 mg sodium ascorbate injection ampul or one 500 mg ascorbic acid tablet and allow to dissolve. Add quantity of distilled water sufficient to make 100 mL. Label “shake well” and “refrigerate.” Stable for 56 days refrigerated or 28 days (ascorbic acid tablet) or 14 days (sodium ascorbate injection) at room temperature.</p>
<div class="reference">Nahata MC, Morosco RS, Hipple TF. Stability of captopril in liquid containing ascorbic acid or sodium ascorbate. <i>Am J Hosp Pharm.</i> 1994;51(13):1707-1708.<span class="pubmed-id">7942898</span></div>
<div class="reference">Nahata MC, Morosco RS, Hipple TF. Stability of captopril in three liquid dosage forms. <i>Am J Hosp Pharm.</i> 1994;51(1):95-96.<span class="pubmed-id">8135269</span></div>
</div>
<div class="block admp drugH1Div" id="F52612360"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach 1 hour before or 2 hours after meals/feeds; administration with food will decrease absorption; consistent administration times are recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Domonoske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Domonoske.1'])">Ref</a></span>). If crushing tablet and dissolving in water, allow adequate time for complete dissolution (&gt;10 minutes) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22468132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22468132'])">Ref</a></span>); may also prepare and administer as an extemporaneous oral liquid.</p></div>
<div class="block adm drugH1Div" id="F802614"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer at least 1 hour before meals. Unstable in aqueous solutions; to prepare solution for oral administration, mix prior to administration and use within 10 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8879325']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8879325'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F25188358"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); protect from moisture.</p></div>
<div class="block usep drugH1Div" id="F53565850"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, and diabetic nephropathy (All indications: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F145421"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Captopril may be confused with calcitriol, Capitrol, carvedilol.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Acepril [Great Britain] may be confused with Accupril which is a brand name for quinapril in the US.</p>
<p style="text-indent:-2em;margin-left:4em;">Acepril: Brand name for captopril [Great Britain], but also the brand name for enalapril [Hungary, Switzerland]; lisinopril [Malaysia].</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F145407"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F145330"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Management: Aliskiren use with ACEIs or ARBs in patients with diabetes is contraindicated. Combined use in other patients should be avoided, particularly when CrCl is less than 60 mL/min. If combined, monitor potassium, creatinine, and blood pressure closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: Angiotensin-Converting Enzyme Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alteplase: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Alteplase. Specifically, the risk for angioedema may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II: Angiotensin-Converting Enzyme Inhibitors may enhance the therapeutic effect of Angiotensin II. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Angiotensin II Receptor Blockers may increase the serum concentration of Angiotensin-Converting Enzyme Inhibitors. Management: Use of telmisartan and ramipril is not recommended. It is not clear if any other combination of an ACE inhibitor and an ARB would be any safer. Consider alternatives when possible. Monitor blood pressure, renal function, and potassium if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the serum concentration of Captopril.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprotinin: May diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AzaTHIOprine: Angiotensin-Converting Enzyme Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipeptidyl Peptidase-IV Inhibitors: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ferric Gluconate: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ferric Hydroxide Polymaltose Complex: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Ferric Hydroxide Polymaltose Complex. Specifically, the risk for angioedema or allergic reactions may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Angiotensin-Converting Enzyme Inhibitors may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gelatin (Succinylated): Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Gelatin (Succinylated). Specifically, the risk of a paradoxical hypotensive reaction may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grass Pollen Allergen Extract (5 Grass Extract): Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). Specifically, ACE inhibitors may increase the risk of severe allergic reaction to Grass Pollen Allergen Extract (5 Grass Extract). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icatibant: May diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Dextran Complex: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of Angiotensin-Converting Enzyme Inhibitors. Management: Administer angiotensin-converting enzyme (ACE) inhibitors at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Angiotensin-Converting Enzyme Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor for increased concentrations/toxic effects of lithium if an ACE inhibitor is initiated/dose increased, or if switching between ACE inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Angiotensin-Converting Enzyme Inhibitors may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pregabalin: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Pregabalin. Specifically, the risk of angioedema may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Racecadotril: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk for angioedema may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sacubitril: Angiotensin-Converting Enzyme Inhibitors may enhance the adverse/toxic effect of Sacubitril. Specifically, the risk of angioedema may be increased with this combination. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Salicylates may diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus Products: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk for angioedema may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Angiotensin-Converting Enzyme Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Angiotensin-Converting Enzyme Inhibitors may enhance the hyperkalemic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: May interact via an unknown mechanism with Angiotensin-Converting Enzyme Inhibitors. Management: Avoid concomitant use of urapidil and angiotensin-converting enzyme (ACE) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: May enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Specifically, the risk of angioedema may be increased.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F145358"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Captopril serum concentrations may be decreased if taken with food. Long-term use of captopril may lead to a zinc deficiency, which can result in altered taste perception. Management: Take on an empty stomach 1 hour before or 2 hours after meals.</p></div>
<div class="block rep_considerations drugH1Div" id="F53746283"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Avoid use of angiotensin-converting enzyme (ACE) inhibitor therapy in patients who may become pregnant and who are not using effective contraception (ADA 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. ACE inhibitors are fetotoxic. Transition patients prior to conception to an agent preferred for use during pregnancy unless treatment with an ACE inhibitor is absolutely necessary (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p>
<p style="text-indent:0em;margin-top:2em;">When ACE inhibitors are used for the treatment of proteinuric chronic kidney disease in patients who could become pregnant, discontinue use at the first positive pregnancy test (ADA 2021; Fakhouri 2022).</p>
<p style="text-indent:0em;margin-top:2em;">ACE inhibitors are not recommended for the treatment of heart failure in patients planning to become pregnant (AHA/ACC/HFSA [Heidenreich 2022]).</p></div>
<div class="block pri drugH1Div" id="F145347"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Captopril crosses the placenta (Hurault de Ligny 1987).</p>
<p style="text-indent:0em;margin-top:2em;">Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Exposure to an angiotensin-converting enzyme (ACE) inhibitor during the first trimester of pregnancy may be associated with an increased risk of fetal malformations (ACOG 2019; ESC [Regitz-Zagrosek 2018]). Following exposure during the second or third trimesters, drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Oligohydramnios may not appear until after an irreversible fetal injury has occurred. ACE inhibitor use during pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Monitor infants exposed to an ACE inhibitor in utero for hyperkalemia, hypotension, and oliguria. Exchange transfusions or dialysis may be required to reverse hypotension or improve renal function</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">ACE inhibitors should be discontinued as soon as possible once pregnancy is detected. When treatment of chronic hypertension in pregnancy is indicated, agents other than ACE inhibitors are recommended (ACOG 2019; ESC [Cífková 2020]; SOGC [Magee 2022]). Use during pregnancy should only be considered for cases of hypertension refractory to other medications (ACOG 2019). Closely monitor pregnant patients on ACE inhibitors with serial ultrasounds.</p>
<p style="text-indent:0em;margin-top:2em;">ACE inhibitors are not recommended for the treatment of heart failure or proteinuric chronic kidney disease during pregnancy (AHA/ACC/HFSA [Heidenreich 2022]; ESC [Regitz-Zagrosek 2018]; Fakhouri 2022).</p></div>
<div class="block mopp drugH1Div" id="F53565851"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, BUN, serum creatinine, renal function, urine dipstick for protein, serum potassium, WBC with differential, especially during first 3 months of therapy for patients with renal impairment and/or collagen vascular disease; monitor for angioedema and anaphylactoid reactions; hypovolemia, postural hypotension, and neurologic status when beginning therapy, adjusting dosage, and on a regular basis throughout</p></div>
<div class="block pha drugH1Div" id="F145324"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion.</p></div>
<div class="block phk drugH1Div" id="F145343"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Within 15 minutes; Peak effect: Blood pressure reduction: 1 to 1.5 hours after dose</p>
<p style="text-indent:-2em;margin-left:2em;">Maximum effect: Antihypertensive: 60 to 90 minutes; may require several weeks of therapy before full hypotensive effect is seen</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Dose related, may require several weeks of therapy before full hypotensive effect</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: 60% to 75%; rapid</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 0.7 L/kg (Duchin 1982)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~60% to 75% (Kubo 1985); reduced 30% to 40% by food</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 25% to 30%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: 50% metabolized</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants with CHF: 3.3 hours; range: 1.2 to 12.4 hours (Pereira 1991)</p>
<p style="text-indent:-2em;margin-left:4em;">Children: 1.5 hours; range: 0.98 to 2.3 hours (Levy 1991)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults, healthy volunteers: ~1.7 hours (Duchin 1982). In 2 studies, patients with chronic kidney failure demonstrated ~2-fold longer half-lives as compared to normal subjects (Giudicelli 1984; Onoyama 1981). Half-life was up to 21 hours in patients with severe kidney impairment and up to 32 hours in patients on chronic hemodialysis in another study (Duchin 1984)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Within 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&gt;95%) within 24 hours (40% to 50% as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F145350"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Acetab | Apo capto | Capocard | Capoten | Captace | Captophar | Midopril</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Capace | Captopril genericon pharma | Debax</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Acenorm | Apo captopril | Capace | Capoten | Captohexal | Captopril bc | Cm captopril | Dbl captopril | Enzace | Sbpa captopril | Topace | Tw captopril | Zedace</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acetor | Angiten | Capotril | Capril | Cardopril | Topril</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Capoten | Capriltop | Captopril bc | Captopril bexal | Captopril eurogenerics | Captopril merck-generics | Captopril ratiopharm | Captopril sandoz | Captopril teva generics belgium | Captoprimed | Doccaptopri</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Captopril denk | Captopril tm</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Alkadil | Capoten | Tensiomin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Abepoten | Antipressin | Aorten | Aortt | Cabioten | Capobal | Capoten | Capotrat | Capotril | Capotrineo | Capox | Capril | Captil | Captobel | Captocord | Captolab | Captolin | Captomax | Captomed | Captomido | Capton | Captophex | Captopiril | Captopril brasterapica | Captopril laqfa | Captopron | Captosen | Captosif | Captotec | Captozen | Ductopril | Farmanguinhos captopril | Furp captopril | Genoptril | Hipocatril | Hipoten | Hipotensil | Iquego captopril | Labopril | Lafepe captopril | Normapril | Pressomax | Presstopril | Prilpressin | Ritpress | Teusil | Venopril</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Capto-basan | Captopril cophar | Captopril mepha | Captopril upsa | Captosol | Lopirin | Tensobon</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Apo capto | Captopril generis | Lopril | Tensoprel</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Capoten | Properil</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bo tong | Capoten | Pu li bo tong</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Altran | Capoten | Captol | Captomed | Captopren | Captopril mk | Cardiopril | Cardopril | Drugsipres | Ecapress | Falaprex | Hipermed | Norpril | Presinorm | Redupres</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alkadil | Apo capto | Capoten | Captopril al | Katopil | Tensiomin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ace hemmer | Ace-hemmer von R.A.N. | Ace-hemmer-ratiopharm | Acenorm | Adocor | Capto | Capto 1a pharma | Capto Corax | Capto dura m | Capto lich | Capto sanorania | Capto-isis | Capto-Puren | Captobeta | Captodoc | Captoflux | Captogamma | Captohexal | Captomerck | Captopress | Captopril 1a pharma | Captopril actavis | Captopril al | Captopril Aristo | Captopril atid | Captopril axsan | Captopril denk | Captopril freemed | Captopril gry | Captopril Pfleger | Captopril sandoz | Captopril Stada | Captopril Temmler | Captopril Verla | Captoreal | Captowieb | Cardiagen | Coronorm | Epicordin | Esparil | Jucapt | Lopirin | Mundil | Phamopril | Sansanal | Sigacap | Tensiomin | Tensobon | Tensostad</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Captopril nm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Capoten | Capril | Captoprilan | Captoril | Ecapres | Fratopril | Tensoprel</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Capoten | Captopril Genfar | Captostar | Librapril</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Angiopress | Angiopril | Capoten | Captohexal | Captopril AbZ | Captopril cox | Kapteks | Katopil | Nycapril | Tensiomin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Acepril | Angiopress | Capoten | Capotil | Capotril | Farcoprel | Farcopril | Hypopress | Lontensin | Lotensine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Alopresin | Capoten | Captopril alter | Captopril Apotex | Captopril apothecon | Captopril bayvit | Captopril bexal | Captopril cinfa | Captopril edigen | Captopril esteve | Captopril mabo | Captopril merck | Captopril mundogen | Captopril normon | Captopril pharmagenus | Captopril ratiopharm | Captopril rubio | Captopril tamarang | Captopril tarbis | Captopril ur | Captosina | Cesplon | Cesplon cor | Dardex | Dilabar | Garanil | Tensoprel</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Capoten | Captomin | Captopril actavis | Captopril alpharma | Captopril generics | Captopril Merck NM | Captopril pliva | Captopril sandoz | Captostad | Lopril</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Captirex | Captolane | Captopril arrow | Captopril Bayer | Captopril biogaran | Captopril g gam | Captopril gnr | Captopril irex | Captopril ivax | Captopril merck | Captopril Qualimed | Captopril ratiopharm | Captopril rpg | Captopril sandoz | Captopril Teva | Captopril Zydus | Lopril | Oltens</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Acepril d.f | Captomex | Captopril cox | Captopril kent | Captopril sandoz | Ecopace | Hyteneze | Kaplon | Tensopril</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Capoten | Hypotensor | Neo ipertas | Normolose | Odupril | Pertacilon | Sancap</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo capto | Capoten | Capril | Captopril Stada | Rilcapton | Tensiomin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Capin | Captogamma | Huma-captoril | Tensiomin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Acendril | Acepress | Capoten | Captensin | Casipril | Dexacap | Farmoten | Forten | Inapril | Locap | Lotensin | Metopril | Otaryl | Otoryl | Praten | Scantensin | Tenofax | Tensicap | Tensobon | Vapril</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Aceomel | Actopril | Capoten | Caprill | Captor | Geroten | Tensopril</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Aceril | Apocapen | Capti</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aceten | Alcoryl | Capotril</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Caporil | Captoneer | Captopril 25 kindi | Captopril 50 kindi | Captopril awa | Captopril mdi | Captosaf</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Acepress | Aceprilex | Capoten | Captopril actavis | Captopril doc | Captopril drm | Captopril eg | Maxipril | Tenpril</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Capocard | Capoten | Midopril | Miniten</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Apopril | Brealin | Capotec | Captopril hexal | Captoril bristol-myers | Captoril sankyo | Captoruna | Captowa | Corocalum | Dowpril | Kapuseal | Katonaplon | Kokapto | Ktplon | Mercapril | Onfrule</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Acetan | Angiopril | Captocos | Captolab | Captopril denk | Cardopril | Ropril</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Adolpan | Capoten | Capril | Captifen | Captil | Captogen | Captonal | Captopril ID | Cutoril | Ketanine | Ketonil | Mecaflil | Samjin captopril | Topril</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Acetab | Capocard | Capoten | Miniten</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Adocor | Apo capoten | Apo captopril | Capoten | Captace | Captopril Genericon | Orbace | Rivtopril | Tensiopril</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Alkadil | Angiopress | Angiopril | Apo capto | Capoten | Capril | Captohexal | Captopril AbZ | Captopril ac | Captopril arena | Captopril bp | Kaptex | Katopil | Novo captopril | Ropril | Tensiomin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Capoten | Captohexal | Captopril Mylan | Doccaptopri</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Alkadil | Angiopress | Angiopril | Capoten | Capril | Captogamma | Captohexal | Captopril gry | Kaptex | Katopil | Novo captopril | Tensiomin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Capen | Convertal | Hipotensil | Lopril</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Altiver | Atrisol | Biodezil | Bioxil | Brucap | Bucamex | Bugazon | Capotena | Capriwen | Captopril darier | Captopril GI | Captopril gi diba | Captopril gi kendr | Captopril gi pharm | Captopril gi serra | Captopril protein | Captopril raam | Captopril silanes | Captopril wandel | Captoser | Captral | Cardipril | Catona | Condabif | Ecapresan | Ecapril | Ecaten | Enlace | Genopril | Hipertex | Ipyrol | Katodem | Kenolan | Keyerpril | Lenpryl | Midrat | Miocap | Neulastrol | Novapres | Ormoten | Ospil | Proldin | Reductel | Reduprec | Rilten | Rodagen | Sabtres | Tenca i | Tensil | Toprilem | Tropisol | Varaxil | Viegnur</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo capto | Apuzin | Capoten | Capriten | Captohexal | Epsitron | Kimafan | Taguar</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">C pril | Donypril | N &amp; n captopril | Taguar</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Capoten | Captopril Accord | Captopril actavis | Captopril katwijk | Captopril ratiopharm | Captoril katwijk</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Capoten | Captopril Mylan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo captopril | Capoten | Captohexal | M captopril</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Caposan | Capoten | Capressior | Captomed | Melatil | Nolectin | Presicaptil</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ace-bloc | Biopril | Bloc Med | Capomed | Capotec | Capoten | Captace | Captobes | Captogen | Captor | Captril | Conamid | Hartylox | Hyperstop | Normil | Primace | Retensin | Ritemed Captopril | Spec Ace | Tensoril | Tgp capto | Typrilace | Unihype | Vasostad</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Acetopril | Aptil | Bentoril | Capace | Capoten | Capril | Captace | Captil | Capto | Catoper | G-cap | Garan | Katopil | Maripril | Nobeten | Plumax | Qutril | Ropril | Tensiomin | Vasokap | Vasotone | Vegaten</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Capoten | Captopril jelfa | Tensiomin | Tensobon</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Capoten</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Calpix | Capoten | Capritin | Captopril merck-generics | Carencil | Convertal | Hipotensil | Pressil | Prilovase | Tensopril | Vidapril</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Acetab | Apo-Capto | Capocard | Farcopril | Hypopress | Lotensine</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Alkadil | Capocard | Capoten | Captopril arena | Captopril eel | Captopril laropharm | Captopril lph | Farcopril | Hypotensor | Kapril</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aceten | Alkadil | Angiopril | Apo capto | Blocordil | Capocard | Capopharm | Capoten | Capto | Captopril akos | Captopril akri | Captopril biosynt | Captopril egis | Captopril fpo | Captopril n.s. | Captopril of | Captopril sandoz | Captopril sar | Captopril stad int | Captopril sti | Captopril Teva | Captopril ubf | Captopril velpharm | Gen captopril | Kapoten | Katopil | Kmp captopril | Novo captopril | Rilcapton | Tensiomin | Vero captopril</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Acetab | Apo captopril | Capocard | Capoten | Captophar | Miniten | Novo captoril</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Captopril actavis | Captopril Mylan | Captopril ratiopharm</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo capto | Capoten | Catoplin | Dexacap | Ketanine | Pertacilon | Rilcapton</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Alkadil | Kaptopril</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Alkadil | Capoten | Katopil | Tensiomin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Capoten | Capril | Epsitron | Gemzil | Tensiomin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Actopril | Capocard | Capril | Capto Pril Alliance | Captolane | Convertal | Lopril | Tensopril</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Kapril | Kaptoril</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Aceloc | Acepril | Aceprotin | Apo capto | Apuzin | Asisten | C.p.t | Cabudan | Calatec | Capdon | Capomil | Caponal | Capoten | Capotil | Capril | Caproine | Captolin | Captolong | Captopin | Captopri | Captrol | Catopren | Ceporin | Hyperten | Kecap | Meriga | Rilcapton | Smarten | Suyea | Tecapril | Vasodil</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Aceten | Capoten | Capotril | Hypotensor | Katopil | Tensiomin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Angiopril | Captopril denk | Epsitron</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Asisten | Capoten | Captopril Pellier | Captopril teuto | Cercor | Isopril | Yaraten</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Capoten | Captopril Penta | Captoril | Captoz | Ceplon | Lidinox | Presinorm | Prileno | Tabulan</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Bidipril</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aceten | Adco-captopril | Apo captopril | Bio Captopril | Capace | Capoten | Captohexal | Captomax | Cardiace | Merck-captopril | Rolab-captopril</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Capril | Kamtopril</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Angiopril | Caipolex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31226134">
<a name="31226134"></a>Adelborg K, Nicolaisen SK, Hasvold P, Palaka E, Pedersen L, Thomsen RW. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients - a population-based cohort study. <i>PLoS One</i>. 2019;14(6):e0218739. doi:10.1371/journal.pone.0218739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/31226134/pubmed" id="31226134" target="_blank">31226134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11408392">
<a name="11408392"></a>Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. <i>Hypertension</i>. 2001;37(6):1440-1443. doi:10.1161/01.hyp.37.6.1440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/11408392/pubmed" id="11408392" target="_blank">11408392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28767167">
<a name="28767167"></a>Alharbi FF, Kholod AAV, Souverein PC, et al. The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case/noncase study in VigiBase. <i>Fundam Clin Pharmacol</i>. 2017;31(6):676-684. doi:10.1111/fcp.12313<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/28767167/pubmed" id="28767167" target="_blank">28767167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12639167">
<a name="12639167"></a>Alkurtass DA, Al-Jazairi AS. Possible captopril-induced toxic epidermal necrolysis. <i>Ann Pharmacother</i>. 2003;37(3):380-383. doi:10.1345/aph.1C284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/12639167/pubmed" id="12639167" target="_blank">12639167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8879325">
<a name="8879325"></a>Allen LV Jr and Erickson MA 3rd, Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. <i>Am J Health-Syst Pharm</i>. 1996;53(18):2179-2184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/8879325/pubmed" id="8879325" target="_blank">8879325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12479763">
<a name="12479763"></a>ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). <i>JAMA.</i> 2002;288(23):2981-2997.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/12479763/pubmed" id="12479763" target="_blank">12479763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2021. <i>Diabetes Care</i>. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed January 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25249586">
<a name="25249586"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; ACC/AHA Task Force Members; Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(25):2354-94. doi:10.1161/CIR.0000000000000133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/25249586/pubmed" id="25249586" target="_blank">25249586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2012448">
<a name="2012448"></a>Angeli P, Chiesa M, Caregaro L, et al. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial. <i>Arch Intern Med</i>. 1991;151(4):678-682.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/2012448/pubmed" id="2012448" target="_blank">2012448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31045940">
<a name="31045940"></a>Ammar H, Chaabane A, Ben Fadhel N, Chadli Z, Ben Fredj N, Aouam K. Drug rash with eosinophilia and systemic symptoms: Captropril, an unusual culprit drug. <i>Dermatitis</i>. 2019;30(3):238-239. doi:10.1097/DER.0000000000000464<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/31045940/pubmed" id="31045940" target="_blank">31045940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15289388">
<a name="15289388"></a>Antman EM, Anbe SC, Alpert JS, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). <i>Circulation.</i> 2004;110(5):588-636.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/15289388/pubmed" id="15289388" target="_blank">15289388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apo-Capto.2013.11">
<a name="Apo-Capto.2013.11"></a>Apo-Capto (captopril) [product monograph]. Weston, Ontario, Canada: Apotex Inc; November 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.2007">
<a name="Aronoff.2007"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007, p. 28.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21518977">
<a name="21518977"></a>Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>Circulation. </i>2011;123(21):2434-2506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/21518977/pubmed" id="21518977" target="_blank">21518977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3031972">
<a name="3031972"></a>Artman M, Graham TP Jr. Guidelines for vasodilator therapy of congestive heart failure in infants and children. <i>Am Heart J</i>. 1987;113(4):994-1005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/3031972/pubmed" id="3031972" target="_blank">3031972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.2017">
<a name="ASHP.2017"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1549277">
<a name="1549277"></a>Bailey RR. Captopril-induced membranous nephropathy. <i>N Z Med J</i>. 1992;105(926):22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/1549277/pubmed" id="1549277" target="_blank">1549277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20130570">
<a name="20130570"></a>Baker-Smith CM, Benjamin DK Jr, Califf RM, et al. Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. <i>Clin Pharmacol Ther. </i>2010;87(6):668-671.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/20130570/pubmed" id="20130570" target="_blank">20130570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10724055">
<a name="10724055"></a>Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? <i>Arch Intern Med</i>. 2000;160(5):685-693.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/10724055/pubmed" id="10724055" target="_blank">10724055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28377081">
<a name="28377081"></a>Banerji A, Blumenthal KG, Lai KH, Zhou L. Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record. <i>J Allergy Clin Immunol Pract</i>. 2017;5(3):744-749. doi:10.1016/j.jaip.2017.02.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/28377081/pubmed" id="28377081" target="_blank">28377081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18489011">
<a name="18489011"></a>Ben Salem C, Chenguel L, Ghariani N, Denguezli M, Hmouda H, Bouraoui K. Captopril-induced lichen planus pemphigoides. <i>Pharmacoepidemiol Drug Saf</i>. 2008;17(7):722-724. doi:10.1002/pds.1618<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/18489011/pubmed" id="18489011" target="_blank">18489011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25058867">
<a name="25058867"></a>Bezalel S, Mahlab-Guri K, Asher I, Werner B, Sthoeger ZM. Angiotensin-converting enzyme inhibitor-induced angioedema. <i>Am J Med</i>. 2015;128(2):120-125. doi:10.1016/j.amjmed.2014.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/25058867/pubmed" id="25058867" target="_blank">25058867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22468132">
<a name="22468132"></a>Bhatt MD, Thomas JE, Mondal TK. Variation in captopril formulations in pharmacies across Canada. <i>Paediatr Child Health</i>. 2011;16(4):e30-e32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/22468132/pubmed" id="22468132" target="_blank">22468132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31119681">
<a name="31119681"></a>Bianchi S, Aucella F, De Nicola L, Genovesi S, Paoletti E, Regolisti G. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. <i>J Nephrol</i>. 2019;32(4):499-516. doi:10.1007/s40620-019-00617-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/31119681/pubmed" id="31119681" target="_blank">31119681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23721258">
<a name="23721258"></a>Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review. <i>BMC Med</i>. 2013;11:141. doi:10.1186/1741-7015-11-141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/23721258/pubmed" id="23721258" target="_blank">23721258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19581505">
<a name="19581505"></a>Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. <i>Hypertension</i>. 2009;54(3):516-523. doi:10.1161/HYPERTENSIONAHA.109.134197<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/19581505/pubmed" id="19581505" target="_blank">19581505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28994183">
<a name="28994183"></a>Brown T, Gonzalez J, Monteleone C. Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature. <i>J Clin Hypertens (Greenwich)</i>. 2017;19(12):1377-1382. doi:10.1111/jch.13097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/28994183/pubmed" id="28994183" target="_blank">28994183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8689816">
<a name="8689816"></a>Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. <i>Clin Pharmacol Ther.</i> 1996;60(1):8-13. doi:10.1016/S0009-9236(96)90161-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/8689816/pubmed" id="8689816" target="_blank">8689816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9218671">
<a name="9218671"></a>Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. <i>JAMA</i>. 1997;278(3):232-233. doi:10.1001/jama.278.3.232<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/9218671/pubmed" id="9218671" target="_blank">9218671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18025295">
<a name="18025295"></a>Byrd JB, Touzin K, Sile S, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. <i>Hypertension</i>. 2008;51(1):141-147. doi:10.1161/HYPERTENSIONAHA.107.096552<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/18025295/pubmed" id="18025295" target="_blank">18025295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CanadianDiabetes.2013">
<a name="CanadianDiabetes.2013"></a>Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. <i>Can J Diabetes. </i>2013;35(suppl 1):1-212.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Capoten.2017.08">
<a name="Capoten.2017.08"></a>Capoten (captopril) [prescribing information]. Spring Valley, NY: Par Pharmaceutical Companies Inc; August 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Captopril.2019.06">
<a name="Captopril.2019.06"></a>Captopril tablets [prescribing information]. Melville, NY: Amici Pharmaceuticals LLC; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3063729">
<a name="3063729"></a>Castro del Castillo A, Rodriguez M, Gonzalez E, Rodriguez F, Estruch J. Dose-response effect of sublingual captopril in hypertensive crises. <i>J Clin Pharmacol</i>. 1988;28(7):667-670.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/3063729/pubmed" id="3063729" target="_blank">3063729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cattran.1">
<a name="Cattran.1"></a>Cattran DC, Appel GB, Coppo R. IgA nephropathy: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2179605">
<a name="2179605"></a>Ceyhan B, Karaaslan Y, Caymaz O, et al. Comparison of sublingual captopril and sublingual nifedipine in hypertensive emergencies. <i>Japan J Pharmacol</i>. 1990;52(2):189-193.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/2179605/pubmed" id="2179605" target="_blank">2179605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24030372">
<a name="24030372"></a>Chaabane A, Fadhl NB, Chadly Z, Fredj NB, Boughattas NA, Aouam K. Captopril-induced DRESS: first reported case confirmed by patch test. <i>Dermatitis</i>. 2013;24(5):255-257. doi:10.1097/DER.0b013e3182a5d86d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/24030372/pubmed" id="24030372" target="_blank">24030372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11034011">
<a name="11034011"></a>Chase MP, Fiarman GS, Scholz FJ, et al. Angioedema of the small bowel due to an angiotensin-converting enzyme inhibitor. <i>J Clin Gastroenterol. </i>2000;31(3):254-257.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/11034011/pubmed" id="11034011" target="_blank">11034011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10606162">
<a name="10606162"></a>Chisi JE, Wdzieczak-Bakala J, Thierry J, Briscoe CV, Riches AC. Captopril inhibits the proliferation of hematopoietic stem and progenitor cells in murine long-term bone marrow cultures. <i>Stem Cells</i>. 1999;17(6):339-344. doi:10.1002/stem.170339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/10606162/pubmed" id="10606162" target="_blank">10606162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12748199">
<a name="12748199"></a>Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. <i>JAMA.</i> 2003;289(19):2560-2572.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/12748199/pubmed" id="12748199" target="_blank">12748199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8709086">
<a name="8709086"></a>Collins DA, Patel S, Eastwood JB, Bourke BE. Favourable outcome of scleroderma renal crisis. <i>J R Soc Med</i>. 1996;89(1):49P-50P.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/8709086/pubmed" id="8709086" target="_blank">8709086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10988282">
<a name="10988282"></a>Conlin P, Moore T, Swartz S, et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. <i>Hypertension.</i> 2000;36(3):461-465.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/10988282/pubmed" id="10988282" target="_blank">10988282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6340620">
<a name="6340620"></a>Cooper RA. Captopril-associated neutropenia. Who is at risk? <i>Arch Intern Med</i>. 1983;143(4):659-660.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/6340620/pubmed" id="6340620" target="_blank">6340620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16760444">
<a name="16760444"></a>Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. <i>N Engl J Med.</i> 2006;354(23):2443-2451.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/16760444/pubmed" id="16760444" target="_blank">16760444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1932674">
<a name="1932674"></a>Crantock L, Prentice R, Powell L. Cholestatic jaundice associated with captopril therapy. <i>J Gastroenterol Hepatol</i>. 1991;6(5):528-530. doi:10.1111/j.1440-1746.1991.tb00899.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/1932674/pubmed" id="1932674" target="_blank">1932674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9322826">
<a name="9322826"></a>Damasceno A, Ferreira B, Patel S, Sevene E, Polónia J. Efficacy of captopril and nifedipine in black and white patients with hypertensive crisis. <i>J Hum Hypertens</i>. 1997;11(8):471-476.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/9322826/pubmed" id="9322826" target="_blank">9322826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7014657">
<a name="7014657"></a>Devlin RG, Fleiss PM. Captopril in human blood and breast milk. <i>J Clin Pharmacol.</i> 1981;21(2):110-113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/7014657/pubmed" id="7014657" target="_blank">7014657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16428706">
<a name="16428706"></a>Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. <i>Chest</i>. 2006;129(1 suppl):169S-173S. doi:10.1378/chest.129.1_suppl.169S<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/16428706/pubmed" id="16428706" target="_blank">16428706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23551721">
<a name="23551721"></a>Doane J, Stults B. Visual hallucinations related to angiotensin-converting enzyme inhibitor use: case reports and review. <i>J Clin Hypertens (Greenwich).</i> 2013;15(4):230-233.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/23551721/pubmed" id="23551721" target="_blank">23551721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Domonoske.1">
<a name="Domonoske.1"></a>Domonoske C. Appendix A: Common neonatal intensive care unit (NICU) medication guidelines. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6381858">
<a name="6381858"></a>Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ. Elimination kinetics of captopril in patients with renal failure. <i>Kid Internat</i>. 1984;25(6):942-947. doi:10.1038/ki.1984.114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/6381858/pubmed" id="6381858" target="_blank">6381858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7037265">
<a name="7037265"></a>Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DN. Captopril kinetics. <i>Clin Pharmacol Ther</i>. 1982;31(4):452-458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/7037265/pubmed" id="7037265" target="_blank">7037265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20093343">
<a name="20093343"></a>Duerr M, Glander P, Diekmann F, Dragun D, Neumayer HH, Budde K. Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. <i>Clin J Am Soc Nephrol</i>. 2010;5(4):703-708. doi:10.2215/CJN.07371009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/20093343/pubmed" id="20093343" target="_blank">20093343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6110936">
<a name="6110936"></a>Edwards CR, Drury P, Penketh A, Damluji SA. Successful reintroduction of captopril following neutropenia. <i>Lancet</i>. 1981;1(8222):723. doi:10.1016/s0140-6736(81)91998-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/6110936/pubmed" id="6110936" target="_blank">6110936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6788292">
<a name="6788292"></a>el-Makri A, Larabi MS, Kechrid C, Belkahia C, Ben Ayed H. Fatal bone-marrow suppression associated with captopril. <i>Br Med J (Clin Res Ed)</i>. 1981;283(6286):277-278. doi:10.1136/bmj.283.6286.277-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/6788292/pubmed" id="6788292" target="_blank">6788292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36481180">
<a name="36481180"></a>Fakhouri F, Schwotzer N, Cabiddu G, et al. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management. <i>Kidney Int.</i> 2022:S0085-2538(22)01015-8. doi:10.1016/j.kint.2022.10.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/36481180/pubmed" id="36481180" target="_blank">36481180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085962">
<a name="25085962"></a>Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):2215-2245. doi:10.1161/CIR.0000000000000105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/25085962/pubmed" id="25085962" target="_blank">25085962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33223015">
<a name="33223015"></a>Flynn JT. The hypertensive neonate. <i>Semin Fetal Neonatal Med</i>. 2020;25(5):101138. doi:10.1016/j.siny.2020.101138<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/33223015/pubmed" id="33223015" target="_blank">33223015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827377">
<a name="28827377"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3);e20171904. doi:10.1542/peds.2017-1904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/28827377/pubmed" id="28827377" target="_blank">28827377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13678872">
<a name="13678872"></a>Fox KM; EURopean Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (The EUROPA Study). <i>Lancet.</i> 2003;362(9386):782-788.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/13678872/pubmed" id="13678872" target="_blank">13678872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10999979">
<a name="10999979"></a>Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. <i>Arch Intern Med</i>. 2000;160(17):2645-2650. doi:10.1001/archinte.160.17.2645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/10999979/pubmed" id="10999979" target="_blank">10999979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3923176">
<a name="3923176"></a>Friedman WF, George BL. Treatment of congestive heart failure by altering loading conditions of the heart. <i>J Pediatr</i>. 1985;106(5):697-706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/3923176/pubmed" id="3923176" target="_blank">3923176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9732010">
<a name="9732010"></a>Friedman IS, Rudikoff D, Phelps RG, Sapadin AN. Captopril-triggered linear IgA bullous dermatosis. <i>Int J Dermatol</i>. 1998;37(8):608-612. doi:10.1046/j.1365-4362.1998.00544.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/9732010/pubmed" id="9732010" target="_blank">9732010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3025754">
<a name="3025754"></a>Fujimura A, Kajiyama H, Ebihara A, Iwashita K, Nomura Y, Kawahara Y. Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis. <i>Nephron</i>. 1986;44(4):324-328. doi:10.1159/000184014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/3025754/pubmed" id="3025754" target="_blank">3025754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18605972">
<a name="18605972"></a>Gantenbein MH, Bauersfeld U, Baenziger O, et al. Side effects of angiotensin converting enzyme inhibitor (captopril) in newborns and young infants. <i>J Perinat Med</i>. 2008;36(5):448-452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/18605972/pubmed" id="18605972" target="_blank">18605972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33418246">
<a name="33418246"></a>Ghaedi F, Etesami I, Aryanian Z, et al. Drug-induced pemphigus: A systematic review of 170 patients. <i>Int Immunopharmacol</i>. 2021;92:107299. doi:10.1016/j.intimp.2020.107299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/33418246/pubmed" id="33418246" target="_blank">33418246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6095887">
<a name="6095887"></a>Giudicelli JF, Chaignon M, Richer C, Giroux B, Guedon J. Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients. <i>Br J Clin Pharmac</i>. 1984;18(5):749-758.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/6095887/pubmed" id="6095887" target="_blank">6095887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8255797">
<a name="8255797"></a>Gleason MM, Roloff JS, Cyran SE, Weber HS, Baylen BG, Myers JL. Captopril-induced bone marrow suppression in two cardiac patients with trisomy 21. <i>Pediatr Cardiol</i>. 1993;14(4):227-229. doi:10.1007/BF00795376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/8255797/pubmed" id="8255797" target="_blank">8255797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. <i>Hypertension</i>. 2014;63(4):878-885. doi: 10.1161/HYP.0000000000000003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31929301">
<a name="31929301"></a>Gorsane I, Ayed TB, Aoudia R, et al. Simultaneous acute pancreatitis and angioedema associated with angiotensin-converting enzyme inhibitor. <i>Saudi J Kidney Dis Transpl</i>. 2019;30(6):1479-1484. doi:10.4103/1319-2442.275498<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/31929301/pubmed" id="31929301" target="_blank">31929301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6354930">
<a name="6354930"></a>Groel JT, Tadros SS, Dreslinski GR, Jenkins AC. Long-term antihypertensive therapy with captopril. <i>Hypertension</i>. 1983;5(5 pt 2):III145-151. doi:10.1161/01.hyp.5.5_pt_2.iii145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/6354930/pubmed" id="6354930" target="_blank">6354930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6140907">
<a name="6140907"></a>Grossman E, Morag B, Nussinovitch N, et al. Clinical use of captopril in Takayasu's disease. <i>Arch Intern Med. </i>1984;144(1):95-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/6140907/pubmed" id="6140907" target="_blank">6140907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28084903">
<a name="28084903"></a>Hallberg P, Persson M, Axelsson T, et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population. <i>Pharmacogenomics</i>. 2017;18(3):201-213. doi:10.2217/pgs-2016-0184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/28084903/pubmed" id="28084903" target="_blank">28084903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27335175">
<a name="27335175"></a>Hashmi HR, Jabbour R, Schreiber Z, Khaja M. Benazepril-induced agranulocytosis: A case report and review of the literature. <i>Am J Case Rep</i>. 2016;17:425-428. doi:10.12659/ajcr.898028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/27335175/pubmed" id="27335175" target="_blank">27335175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6753907">
<a name="6753907"></a>Havelka J, Boerlin HJ, Studer A, et al. Long-term experience with captopril in severe hypertension. <i>Br J Clin Pharmacol</i>. 1982;14 suppl 2(suppl 2):71S-76S. doi:10.1111/j.1365-2125.1982.tb02060.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/6753907/pubmed" id="6753907" target="_blank">6753907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29808707">
<a name="29808707"></a>Helmer A, Slater N, Smithgall S. A review of ACE inhibitors and ARBs in black patients with hypertension. <i>Ann Pharmacother</i>. 2018;52(11):1143-1151. doi:10.1177/1060028018779082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/29808707/pubmed" id="29808707" target="_blank">29808707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation.</i> 2011;124(23):2610-2642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33491908">
<a name="33491908"></a>Hofmann GA, Weber B. Drug-induced photosensitivity: culprit drugs, potential mechanisms and clinical consequences. <i>J Dtsch Dermatol Ges</i>. 2021;19(1):19-29. doi:10.1111/ddg.14314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/33491908/pubmed" id="33491908" target="_blank">33491908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3306419">
<a name="3306419"></a>Hurault de Ligny BH, Ryckelynck JP, Mintz P, Levy G, Muller G. Captopril therapy in preeclampsia. <i>Nephron</i>. 1987;46(3):329-330.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/3306419/pubmed" id="3306419" target="_blank">3306419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1616218">
<a name="1616218"></a>Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. <i>Ann Intern Med</i>. 1992;117(3):234-242. doi:10.7326/0003-4819-117-3-234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/1616218/pubmed" id="1616218" target="_blank">1616218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2937293">
<a name="2937293"></a>Jaffe IA. Adverse effects profile of sulfhydryl compounds in man. <i>Am J Med</i>. 1986;80(3):471-476. doi:10.1016/0002-9343(86)90722-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/2937293/pubmed" id="2937293" target="_blank">2937293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520. doi:10.1001/jama.2013.284427<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2014;130(23):e199-e267. doi:10.1161/CIR.0000000000000041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10879671">
<a name="10879671"></a>Kammerl MC, Schaefer RM, Schweda F, Schreiber M, Riegger GA, Krämer BK. Extracorporal therapy with AN69 membranes in combination with ACE inhibition causing severe anaphylactoid reactions: still a current problem? <i>Clin Nephrol.</i> 2000;53(6):486-488.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/10879671/pubmed" id="10879671" target="_blank">10879671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23161035">
<a name="23161035"></a>Karakilic E, Buyukcam F, Kocalar G, Gedik S, Atalar E. Same effect of sublingual and oral captopril in hypertensive crisis. <i>Eur Rev Med Pharmacol Sci</i>. 2012;16(12):1642-1645.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/23161035/pubmed" id="23161035" target="_blank">23161035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24788967">
<a name="24788967"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/24788967/pubmed" id="24788967" target="_blank">24788967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2012">
<a name="KDIGO.2012"></a>Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in chronic kidney disease. <i>Kidney Inter Suppl. </i>2012;2(5):v-405.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36272764">
<a name="36272764"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int.</i> 2022;102(suppl 5):S1-S127. doi:10.1016/j.kint.2022.06.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/36272764/pubmed" id="36272764" target="_blank">36272764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33637192">
<a name="33637192"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. <i>Kidney Int.</i> 2021b;99 (3S):S1-S87. doi:10.1016/j.kint.2020.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/33637192/pubmed" id="33637192" target="_blank">33637192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25018935">
<a name="25018935"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Chapter 10: immunoglobulin A nephropathy. <i>Kidney Int Suppl (2011)</i>. 2012;2(2):209-217. doi:10.1038/kisup.2012.23<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/25018935/pubmed" id="25018935" target="_blank">25018935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. <i>Kidney Inter Suppl. </i>2013;3:1-150.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34556256">
<a name="34556256"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. <i>Kidney Int</i>. 2021a;100(suppl 4):S1-S276. doi:10.1016/j.kint.2021.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/34556256/pubmed" id="34556256" target="_blank">34556256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11265073">
<a name="11265073"></a>Kocab MA, Coppola D, Hiotis S, Karl RC, Barthel JS. Captopril-associated cholestasis complicating the management of pancreatic cancer. <i>Surg Endosc</i>. 2000;14(7):681. doi:10.1007/s004640020082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/11265073/pubmed" id="11265073" target="_blank">11265073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16043683">
<a name="16043683"></a>Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. <i>Arch Intern Med</i>. 2005;165(14):1637-1642. doi:10.1001/archinte.165.14.1637<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/16043683/pubmed" id="16043683" target="_blank">16043683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29884969">
<a name="29884969"></a>Kostis WJ, Shetty M, Chowdhury YS, Kostis JB. ACE inhibitor-induced angioedema: a review. <i>Curr Hypertens Rep</i>. 2018;20(7):55. doi:10.1007/s11906-018-0859-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/29884969/pubmed" id="29884969" target="_blank">29884969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6337741">
<a name="6337741"></a>Kramer BL, Massie BM, Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. <i>Circulation</i>. 1983;67(4):807-816. doi:10.1161/01.cir.67.4.807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/6337741/pubmed" id="6337741" target="_blank">6337741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2994938">
<a name="2994938"></a>Kubo SH, Cody RJ. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. <i>Clin Pharmacokin</i>. 1985;10(5):377-391.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/2994938/pubmed" id="2994938" target="_blank">2994938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7904616">
<a name="7904616"></a>Kuechle MK, Stegemeir E, Maynard B, Gibson LE, Leiferman KM, Peters MS. Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. <i>J Am Acad Dermatol</i>. 1994;30(2 Pt 1):187-192. doi:10.1016/s0190-9622(94)70015-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/7904616/pubmed" id="7904616" target="_blank">7904616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21220873">
<a name="21220873"></a>Kumari R, Timshina DK, Thappa DM. Drug hypersensitivity syndrome. <i>Indian J Dermatol Venereol Leprol</i>. 2011;77(1):7-15. doi:10.4103/0378-6323.74964<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/21220873/pubmed" id="21220873" target="_blank">21220873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22477817">
<a name="22477817"></a>Lee GJ, Cohen R, Chang AC, Cleary JP. Angiotensin converting enzyme inhibitor (ACEI)-induced acute renal failure in premature newborns with congenital heart disease. <i>J Pediatr Pharmacol Ther</i>. 2010;15(4):290-296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/22477817/pubmed" id="22477817" target="_blank">22477817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Levy.1991">
<a name="Levy.1991"></a>Levy M, Koren G, Klein J, et al. Captopril pharmacokinetics, blood pressure response and plasma renin activity in normotensive children with renal scarring. <i>Dev Pharmacol Ther. </i>1991;16(4):185-193.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8413456">
<a name="8413456"></a>Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group [published correction appears in <i>N Engl J Med</i>. 1993;330(2):152]. <i>N Engl J Med</i>. 1993;329(20):1456-1462.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/8413456/pubmed" id="8413456" target="_blank">8413456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24233240">
<a name="24233240"></a>Lindle KA, Dinh K, Moffett BS, et al. Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease. <i>Pediatr Cardiol</i>. 2014;35(3):499-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/24233240/pubmed" id="24233240" target="_blank">24233240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9874028">
<a name="9874028"></a>Lluch-Bernal M, Novalbos A, Umpierrez A, Figueredo E, Bombin C, Sastre J. Cutaneous reaction to captopril with positive patch test and lack of cross-sensitivity to enalapril and benazepril. <i>Contact Dermatitis</i>. 1998;39(6):316-367. doi:10.1111/j.1600-0536.1998.tb05952.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/9874028/pubmed" id="9874028" target="_blank">9874028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.2">
<a name="Mann.2"></a>Mann JFE, Bakris GL. Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3133043">
<a name="3133043"></a>Markusse HM, Meyboom RH. Gynaecomastia associated with captopril. <i>Br Med J (Clin Res Ed)</i>. 1988;296(6631):1262-1263. doi:10.1136/bmj.296.6631.1262-c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/3133043/pubmed" id="3133043" target="_blank">3133043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32496628">
<a name="32496628"></a>Maroteau C, Siddiqui MK, Veluchamy A, et al; PREDICTION-ADR. Exome sequencing reveals common and rare variants in F5 associated with ACE inhibitor and angiotensin receptor blocker-induced angioedema. <i>Clin Pharmacol Ther.</i> 2020;108(6):1195-1202. doi:10.1002/cpt.1927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/32496628/pubmed" id="32496628" target="_blank">32496628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11834188">
<a name="11834188"></a>Martínez JC, Fuentes MJ, Armentia A, Vega JM, Fernández A. Dermatitis to captopril. <i>Allergol Immunopathol (Madr)</i>. 2001;29(6):279-280. doi:10.1016/s0301-0546(01)79071-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/11834188/pubmed" id="11834188" target="_blank">11834188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9201818">
<a name="9201818"></a>Mastrobattista JM. Angiotensin converting enzyme inhibitors in pregnancy. <i>Semin Perinatol</i>. 1997;21(2):124-134. doi: 10.1016/s0146-0005(97)80055-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/9201818/pubmed" id="9201818" target="_blank">9201818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyer.1">
<a name="Meyer.1"></a>Meyer TE. Primary pharmacologic therapy of heart failure with reduced ejection fraction in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18413488">
<a name="18413488"></a>Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. <i>Hypertension.</i> 2008;51(6):1624-1630. doi:10.1161/HYPERTENSIONAHA.108.110270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/18413488/pubmed" id="18413488" target="_blank">18413488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3073076">
<a name="3073076"></a>Mimran A, Insua A, Ribstein J, Bringer J, Monnier L. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. <i>Diabetes Care</i>. 1988;11(10):850-853. doi:10.2337/diacare.11.10.850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/3073076/pubmed" id="3073076" target="_blank">3073076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3889818">
<a name="3889818"></a>Mirkin BL, Newman TJ. Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group. <i>Pediatrics.</i> 1985;75(6):1091-1100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/3889818/pubmed" id="3889818" target="_blank">3889818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16494512">
<a name="16494512"></a>Momma K. ACE inhibitors in pediatric patients with heart failure. <i>Paediatr Drugs.</i> 2006;8(1):55-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/16494512/pubmed" id="16494512" target="_blank">16494512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31835086">
<a name="31835086"></a>Montinaro V, Cicardi M. ACE inhibitor-mediated angioedema. <i>Int Immunopharmacol.</i> 2020;78:106081. doi:10.1016/j.intimp.2019.106081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/31835086/pubmed" id="31835086" target="_blank">31835086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15482412">
<a name="15482412"></a>Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. <i>J Eval Clin Pract</i>. 2004;10(4):499-509. doi:10.1111/j.1365-2753.2003.00484.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/15482412/pubmed" id="15482412" target="_blank">15482412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1614676">
<a name="1614676"></a>Moussa Z, Schiano T, Spatoliatore G, Salman S. Neutropenia induced by low-dose captopril. <i>N Y State J Med</i>. 1992;92(5):219-220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/1614676/pubmed" id="1614676" target="_blank">1614676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30672376">
<a name="30672376"></a>Mu G, Xiang Q, Zhou S, et al. Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis. <i>Pharmacogenomics</i>. 2019;20(3):189-212. doi:10.2217/pgs-2018-0157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/30672376/pubmed" id="30672376" target="_blank">30672376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32397904">
<a name="32397904"></a>Mu G, Xiang Q, Zhang Z, et al. <i>PNPT1</i> and <i>PCGF3</i> variants associated with angiotensin-converting enzyme inhibitor-induced cough: a nested case-control genome-wide study. <i>Pharmacogenomics</i>. 2020;21(9):601-614. doi:10.2217/pgs-2019-0167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/32397904/pubmed" id="32397904" target="_blank">32397904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17363396">
<a name="17363396"></a>Mulla H, Tofeig M, Bu'Lock F, et al. Variations in captopril formulations used to treat children with heart failure: a survey in the United Kingdom. <i>Arch Dis Child</i>. 2007;92(5):409-411.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/17363396/pubmed" id="17363396" target="_blank">17363396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22419718">
<a name="22419718"></a>Nanba K, Tamanaha T, Nakao K, et al. Confirmatory testing in primary aldosteronism. <i>J Clin Endocrinol Metab</i>. 2012;97(5):1688-1694. doi: 10.1210/jc.2011-2504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/22419718/pubmed" id="22419718" target="_blank">22419718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.2012">
<a name="NIH.2012"></a>National Heart, Lung, and Blood Institute, National Institutes of Health. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. <i>Clinical Practice Guidelines</i>, 2012. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. <i>Pediatrics</i>, 2004, 114(2)(suppl):555-576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence. Drug allergy: Diagnosis and management. Clinical guideline 183. September 2014. www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2">
<a name="NICE.2"></a>National Institute for Health and Care Excellence (NICE). NICE guideline hypertension in pregnancy: diagnosis and management. www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3294363">
<a name="3294363"></a>O'Dea RF, Mirkin BL, Alward CT, Sinaiko AR. Treatment of neonatal hypertension with captopril. <i>J Pediatr</i>. 1988;113(2):403-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/3294363/pubmed" id="3294363" target="_blank">3294363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425. doi:10.1161/CIR.0b013e3182742cf6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32291375">
<a name="32291375"></a>Oktaviono YH, Kusumawardhani N. Hyperkalemia associated with angiotensin converting enzyme inhibitor or angiotensin receptor blockers in chronic kidney disease. <i>Acta Med Indones</i>. 2020;52(1):74-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/32291375/pubmed" id="32291375" target="_blank">32291375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33229116">
<a name="33229116"></a>Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/33229116/pubmed" id="33229116" target="_blank">33229116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7030952">
<a name="7030952"></a>Onoyama K, Hirakata H, Iseki K, et al. Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure. <i>Hypertension</i>. 1981;3(4):456-459.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/7030952/pubmed" id="7030952" target="_blank">7030952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20530146">
<a name="20530146"></a>Orchard EA, Apps A, Wilson N. Use of captopril in paediatric congestive cardiac failure: early effects on blood pressure and renal function. <i>Arch Dis Child.</i> 2010;95(7):566-567.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/20530146/pubmed" id="20530146" target="_blank">20530146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7848615">
<a name="7848615"></a>Os I, Bratland B, Dahlöf B, Gisholt K, Syvertsen JO, Tretli S. Female preponderance for lisinopril-induced cough in hypertension. <i>Am J Hypertens</i>. 1994;7(11):1012-1015. doi:10.1093/ajh/7.11.1012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/7848615/pubmed" id="7848615" target="_blank">7848615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8862965">
<a name="8862965"></a>Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. <i>Drug Saf</i>. 1996;15(1):72-78. doi:10.2165/00002018-199615010-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/8862965/pubmed" id="8862965" target="_blank">8862965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10587334">
<a name="10587334"></a>Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. <i>Circulation.</i> 1999;100(23):2312-2318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/10587334/pubmed" id="10587334" target="_blank">10587334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15295051">
<a name="15295051"></a>Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. <i>N Engl J Med</i>. 2004;351(6):585-592. doi:10.1056/NEJMra035279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/15295051/pubmed" id="15295051" target="_blank">15295051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.2014">
<a name="Park.2014"></a>Park MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12271008">
<a name="12271008"></a>Peces R. Anaphylactoid reaction induced by ACEI during haemodialysis with a surface-treated AN69 membrane. <i>Nephrol Dial Transplant</i>. 2002;17(10):1859-1860. doi:10.1093/ndt/17.10.1859<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/12271008/pubmed" id="12271008" target="_blank">12271008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pereira.1991">
<a name="Pereira.1991"></a>Pereira CM, Tam YK, Collins-Nakai RL. The pharmacokinetics of captopril in infants with congestive heart failure. <i>Ther Drug Monit.</i> 1991;13(3):209-214.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perkovic.1">
<a name="Perkovic.1"></a>Perkovic V. Treatment of diabetic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 2, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2642619">
<a name="2642619"></a>Perlman JM, Volpe JJ. Neurologic complications of captopril treatment of neonatal hypertension. <i>Pediatrics</i>. 1989;83(1):47-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/2642619/pubmed" id="2642619" target="_blank">2642619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9193433">
<a name="9193433"></a>Pfeffer MA, Greaves SC, Arnold JM, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The Healing and Early Afterload Reducing Therapy Trial. <i>Circulation.</i> 1997;95(12):2643-2651.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/9193433/pubmed" id="9193433" target="_blank">9193433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14610160">
<a name="14610160"></a>Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>N Engl J Med.</i> 2003;349(20):1893-1906.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/14610160/pubmed" id="14610160" target="_blank">14610160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7955473">
<a name="7955473"></a>Phillips WG, Vaughan-Jones S, Jenkins R, Breathnach SM. Captopril-induced lichenoid eruption. <i>Clin Exp Dermatol</i>. 1994;19(4):317-320. doi:10.1111/j.1365-2230.1994.tb01203.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/7955473/pubmed" id="7955473" target="_blank">7955473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27490717">
<a name="27490717"></a>Prieto-García L, Pericacho M, Sancho-Martínez SM, et al. Mechanisms of triple whammy acute kidney injury. <i>Pharmacol Ther</i>. 2016;167:132-145. doi:10.1016/j.pharmthera.2016.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/27490717/pubmed" id="27490717" target="_blank">27490717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16427219">
<a name="16427219"></a>Quan A . Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. <i>Early Hum Dev.</i> 2006;82(1):23-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/16427219/pubmed" id="16427219" target="_blank">16427219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21883995">
<a name="21883995"></a>Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>Cardiovasc Ther</i>. 2012;30(3):e156-e166. doi:10.1111/j.1755-5922.2010.00258.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/21883995/pubmed" id="21883995" target="_blank">21883995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9437375">
<a name="9437375"></a>Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? <i>Arch Intern Med</i>. 1998;158(1):26-32. doi:10.1001/archinte.158.1.26<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/9437375/pubmed" id="9437375" target="_blank">9437375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22754420">
<a name="22754420"></a>Rosenbaum AJ, Luciano JA, Marburger R, Hume E. Acute kidney injury in the setting of knee arthroplasty: a case report and discussion investigating Angiotensin-converting enzyme inhibitors as the culprit. <i>HSS J</i>. 2011;7(2):183-186. doi:10.1007/s11420-010-9189-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/22754420/pubmed" id="22754420" target="_blank">22754420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498. doi: 10.1016/j.jash.2015.03.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases practice guideline management of adult patients with ascites due to cirrhosis 2012. <i>Hepatology</i>. 2013;57(4):1651-1653. doi:10.1002/hep.26359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992489">
<a name="25992489"></a>Sato A, Fukuda S. A prospective study of frequency and characteristics of cough during ACE inhibitor treatment. <i>Clin Exp Hypertens</i>. 2015;37(7):563-568. doi:10.3109/10641963.2015.1026040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/25992489/pubmed" id="25992489" target="_blank">25992489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3308715">
<a name="3308715"></a>Scammell AM, Arnold R, Wilkinson JL. Captopril in treatment of infant heart failure: a preliminary report. <i>Int J Cardiol</i>. 1987;16(3):295-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/3308715/pubmed" id="3308715" target="_blank">3308715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11602506">
<a name="11602506"></a>Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS; Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. <i>Circulation</i>. 2001;104(16):1985-1991. doi:10.1161/hc4101.096153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/11602506/pubmed" id="11602506" target="_blank">11602506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31888533">
<a name="31888533"></a>Scott J, Jones T, Redaniel MT, May MT, Ben-Shlomo Y, Caskey F. Estimating the risk of acute kidney injury associated with use of diuretics and renin angiotensin aldosterone system inhibitors: A population based cohort study using the clinical practice research datalink. <i>BMC Nephrol</i>. 2019;20(1):481. doi:10.1186/s12882-019-1633-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/31888533/pubmed" id="31888533" target="_blank">31888533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3284479">
<a name="3284479"></a>Shaw NJ, Wilson N, Dickinson DF. Captopril in heart failure secondary to a left to right shunt. <i>Arch Dis Child</i>. 1988;63(4):360-363.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/3284479/pubmed" id="3284479" target="_blank">3284479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2840522">
<a name="2840522"></a>Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. <i>JAMA</i>. 1988;260(7):967-970.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/2840522/pubmed" id="2840522" target="_blank">2840522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22052934">
<a name="22052934"></a>Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. <i>Circulation.</i> 2011;124(22):2458-4573.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/22052934/pubmed" id="22052934" target="_blank">22052934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9824192">
<a name="9824192"></a>Smoger SH, Sayed MA. Simultaneous mucosal and small bowel angioedema due to captopril. <i>South Med J.</i> 1998;91(11):1060-1063.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/9824192/pubmed" id="9824192" target="_blank">9824192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6212200">
<a name="6212200"></a>Solinger AM. Exfoliative dermatitis from captopril. <i>Cutis</i>. 1982;29(5):473-474.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/6212200/pubmed" id="6212200" target="_blank">6212200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29808264">
<a name="29808264"></a>Starr MC, Flynn JT. Neonatal hypertension: cases, causes, and clinical approach. <i>Pediatr Nephrol</i>. 2019;34(5):787-799. doi:10.1007/s00467-018-3977-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/29808264/pubmed" id="29808264" target="_blank">29808264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3526889">
<a name="3526889"></a>Suarez M, Ho PW, Johnson ES, Perez G. Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy. <i>Am J Med</i>. 1986;81(2):336-338. doi:10.1016/0002-9343(86)90274-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/3526889/pubmed" id="3526889" target="_blank">3526889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3906398">
<a name="3906398"></a>Taguma Y, Kitamoto Y, Futaki G, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. <i>N Engl J Med</i>. 1985;313(26):1617-1620. doi:10.1056/NEJM198512263132601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/3906398/pubmed" id="3906398" target="_blank">3906398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15228574">
<a name="15228574"></a>Tarcan A, Gürakan B, Ozbek N. Captopril-induced pancytopenia in a premature newborn. <i>J Paediatr Child Health</i>. 2004;40(7):404-405. doi:10.1111/j.1440-1754.2004.00412.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/15228574/pubmed" id="15228574" target="_blank">15228574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva-Captopril.2021.02">
<a name="Teva-Captopril.2021.02"></a>Teva-Captopril (captopril) tablets, USP [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17323037">
<a name="17323037"></a>Trimble MA, Sketch MH Jr, Mehta RH. Hemolytic anemia: a rare but potentially serious adverse effect of captopril. <i>Herz</i>. 2007;32(1):62-64. doi:10.1007/s00059-007-2956-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/17323037/pubmed" id="17323037" target="_blank">17323037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tschollar.1985">
<a name="Tschollar.1985"></a>Tschollar W, Belz GG. Sublingual captopril in hypertensive crisis. <i>Lancet</i>. 1985;2(8445):34-35.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7011347">
<a name="7011347"></a>Vandenburg M, Parfrey P, Wright P, Lazda E. Hepatitis associated with captopril treatment. <i>Br J Clin Pharmacol</i>. 1981;11(1):105-106. doi:10.1111/j.1365-2125.1981.tb01116.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/7011347/pubmed" id="7011347" target="_blank">7011347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Varon.1">
<a name="Varon.1"></a>Varon J, Elliott W. Management of severe asymptomatic hypertension (hypertensive urgencies) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6237623">
<a name="6237623"></a>Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. <i>Arch Intern Med.</i> 1984;144(10):1947-1953.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/6237623/pubmed" id="6237623" target="_blank">6237623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10644922">
<a name="10644922"></a>von Vigier RO, Mozzettini S, Truttmann AC, et al. Cough is common in children prescribed converting enzyme inhibitors. <i>Nephron. </i>2000;84(1):98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/10644922/pubmed" id="10644922" target="_blank">10644922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3064605">
<a name="3064605"></a>Weber MA. Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors. <i>Am J Med</i>. 1988;84(4A):16-23. doi:10.1016/0002-9343(88)90465-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/3064605/pubmed" id="3064605" target="_blank">3064605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10619572">
<a name="10619572"></a>Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency? <i>Am J Hypertens</i>. 1999;12(12 Pt 3):195S-203S. doi:10.1016/s0895-7061(99)00104-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/10619572/pubmed" id="10619572" target="_blank">10619572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20150448">
<a name="20150448"></a>Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. <i>Clin J Am Soc Nephrol</i>. 2010;5(3):531-548. doi:10.2215/CJN.07821109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/20150448/pubmed" id="20150448" target="_blank">20150448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.<i> Hypertension</i>. 2018;71(6):e13-e115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10498172">
<a name="10498172"></a>Winfred RI, Nanda S, Horvath G, Elnicki M. Captopril-induced toxic epidermal necrolysis and agranulocytosis successfully treated with granulocyte colony-stimulating factor. <i>South Med J.</i> 1999;92(9):918-920. doi:10.1097/00007611-199909000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/10498172/pubmed" id="10498172" target="_blank">10498172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20625347">
<a name="20625347"></a>Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. <i>Pharmacogenet Genomics.</i> 2010;20(9):532-536. doi:10.1097/FPC.0b013e32833d3acb<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/20625347/pubmed" id="20625347" target="_blank">20625347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2002">
<a name="WHO.2002"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20117105">
<a name="20117105"></a>Wu VC, Kuo CC, Chang HW, et al. Diagnosis of primary aldosteronism: comparison of post-captopril active renin concentration and plasma renin activity. <i>Clin Chim Acta</i>. 2010;411(9-10):657-663.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/20117105/pubmed" id="20117105" target="_blank">20117105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23747642">
<a name="23747642"></a>Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2013;62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/23747642/pubmed" id="23747642" target="_blank">23747642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8703645">
<a name="8703645"></a>Yeo WW, Chadwick IG, Kraskiewicz M, Jackson PR, Ramsay LE. Resolution of ACE inhibitor cough: changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance-P. <i>Br J Clin Pharmacol</i>. 1995;40(5):423-429.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/8703645/pubmed" id="8703645" target="_blank">8703645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10639539">
<a name="10639539"></a>Yusuf S, Sleight P, Pogue J, et al; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. <i>N Engl J Med.</i> 2000;342(3):145-153. doi:10.1056/NEJM200001203420301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/captopril-pediatric-drug-information/abstract-text/10639539/pubmed" id="10639539" target="_blank">10639539</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13112 Version 381.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
